TIDMAGY
RNS Number : 8818X
Allergy Therapeutics PLC
03 September 2020
Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the
"Group"), Saiba AG
("Saiba") and DeepVax GmbH ("DeepVax")
Allergy Therapeutics secures virus-like particle ("VLP")
technology platform to broaden vaccine pipeline through licensing
agreements with Saiba AG and DeepVax GmbH
- Group to investigate potential of VLP technology in oncology
and other immune conditions after encouraging proof of concept
findings
- Builds on positive ongoing progress in VLP-based peanut allergy candidate vaccine
- VLP platform to be combined with Allergy Therapeutics' proprietary adjuvant technology
3 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, today announces further investment in virus-like particle
(VLP) technology for applications beyond the allergy immunotherapy
field. Allergy therapeutics (the Group) entered into an exclusive
licence agreement with Saiba AG and DeepVax GmbH to use their
patented VLP technology platform to develop and commercialise
vaccines targeting solid cancer tumours, atopic dermatitis, asthma,
and psoriasis.
Allergy Therapeutics has an existing license agreement with
Saiba and DeepVax , exclusively licensing their technology for the
Group's development of a new VLP vaccine immunotherapy treatment
for peanut allergy sufferers. Submission of the clinical trial
application for that candidate vaccine is anticipated in 2021 and
follows previously published encouraging preclinical results(1)
.
The latest licensing agreement with Saiba and DeepVax includes
upfront payments, which are not material in Group terms, plus
further milestone payments at key points in clinical development,
as well as royalty payments if candidates are commercialised.
The Group believes the use of VLP technology is a novel approach
to generating active vaccines against appropriate cytokines, the
small proteins that are crucial to cell signalling in the immune
pathway for many diseases. Current approaches, including monoclonal
antibodies, can have the limitation of a transient effect meaning
repeated treatments are required. The Group believes the VLP
approach could offer many benefits including sustained efficacy and
a much lower cost per patient.
In pursuing this approach, Allergy Therapeutics intends to
investigate the potential of combining VLP technology with its
adjuvant systems including MCT (microcrystalline tyrosine).
Adjuvant technologies are a key element of Allergy Therapeutics'
strategy and have the potential to create immunotherapies that act
faster, generate a sustained response, and work more efficiently
than traditional therapies. Prior studies have already demonstrated
the Group's adjuvant technologies have a synergistic effect in
certain disease models(2) .
The Group plans to evaluate these new therapies via initial
pre-clinical evaluation and, should these studies be successful,
will explore future clinical development and potential partnering
opportunities, alongside discussions with regulatory
authorities.
Manuel Llobet, CEO at Allergy Therapeutics , stated: "This is a
very exciting opportunity for Allergy Therapeutics, enabling us to
take the first steps into the broader vaccine field using a
technology platform that we are familiar with and already using in
our peanut allergy candidate vaccine. While the allergy field
remains our core focus, we believe VLP technology has potential
across multiple therapies areas where there remains huge unmet need
among patients. This is an opportunity to provide significant
improvements to current treatment approaches used for a number of
solid cancer and immune conditions and a more convenient treatment
option for patients, which is the founding principle of our
business."
Martin Bachmann, Founder of Saiba and CSO of DeepVax, stated:
"This is a very important opportunity and milestone for Saiba and
DeepVax. It advances four of our major programs towards clinical
status and proof-of-concept. In addition, it reflects an important
progression and validation of our CuMVtt-VLP platform."
This announcement contains inside information for the purposes
of Article 7 of Regulatory (EU) No596/2014.
- ENDS -
References
1. Allergy Therapeutics publishes encouraging new data for
peanut allergy vaccine candidate in The Journal of Allergy and
Clinical Immunology, 29 January 2020,
https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=14586336
2. Cabral-Miranda et al., Virus-Like Particle (VLP) Plus
Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy
Improving T and B Cell Immunogenicity and Protection against
Plasmodium berghei/Vivax. Vaccines 2017, 5, 10;
doi:10.3390/vaccines5020010
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Saiba AG
+41 (44) 515 4133
Patrik M. Paulus, Executive Chairman
Dr. Gary Jennings, COO
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
James Stearns, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development include vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Adjuvant systems to boost performance of vaccines outside allergy
are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved over 9% compound annual
growth since formation, employs c.500 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com .
About Saiba AG
Saiba AG, headquartered in Pfäffikon (Schwyz) Switzerland, is
built on a solid foundation of experience, know-how and
intellectual property in vaccine research and development. Its
patented VLP technology and core projects help clients to define,
explore and develop vaccination strategies for their needs, which
include infectious and chronic diseases. Virus-like particles
(VLPs) are the most immunogenic recombinant scaffold for display of
antigens with strong Proof-of-Concept (PoC) in humans. Saiba AG's
proprietary technology has enabled its scientists to generate a
vaccine candidate against COVID-19 with preclinical proof of
concept, and they have significantly invested in their discovery
and clinical capabilities. With the effective control of many
infectious diseases in many parts of the world, chronic, often
non-communicable diseases have become the single largest cause of
death and disability. Treatment of such chronic diseases is
expensive and often ineffective. There is a major need for novel
treatment modalities such as therapeutic immunization to prevent
rather than treat chronic diseases and that are available at
affordable costs. For more information, please see
www.saiba-biotech.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLLLBBKLZBBX
(END) Dow Jones Newswires
September 03, 2020 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024